Top 10 Trihexyphenidyl (Artane) Generic Manufacturers in China
The trihexyphenidyl market has witnessed significant growth, particularly in the Asian region, driven by the increasing prevalence of movement disorders such as Parkinson’s disease and the rise in geriatric populations. In 2022, the global market for trihexyphenidyl was valued at approximately USD 200 million, with expectations to grow at a compound annual growth rate (CAGR) of 6% through 2028. China, as a major pharmaceutical hub, has become a key player in the production of this medication, contributing to both local and international demands.
1. Zhejiang Huahai Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical is one of the leading manufacturers of trihexyphenidyl in China, with an annual production capacity of over 200 million tablets. The company holds approximately 15% of the local market share, exporting to more than 20 countries across Asia, Europe, and North America.
2. Hunan Er-Kang Pharmaceutical Co., Ltd.
Hunan Er-Kang is a prominent player in the generics market, producing trihexyphenidyl with a production volume of around 150 million units annually. Their commitment to quality has helped them capture about 10% of the domestic market and establish a foothold in Southeast Asia.
3. Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui is a major pharmaceutical company known for its wide range of products, including trihexyphenidyl. The company produces around 100 million tablets per year and is recognized for its strong export performance, accounting for 8% of the Chinese export market for the drug.
4. Shanghai Pharmaceuticals Holding Co., Ltd.
With an extensive distribution network, Shanghai Pharmaceuticals produces approximately 80 million units of trihexyphenidyl annually. The company’s innovative approach and strategic partnerships have enabled it to maintain a market share of 7%, focusing primarily on the domestic market.
5. Shandong Xinhua Pharmaceutical Company Limited
Shandong Xinhua is another key manufacturer, producing trihexyphenidyl with an output of 70 million tablets per year. The company holds about 6% of the market share in China, with a growing presence in export markets, particularly in Latin America.
6. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Guangzhou Baiyunshan has a diverse portfolio and produces approximately 60 million tablets of trihexyphenidyl annually. The company’s market strategies have allowed it to capture a 5% share, serving both local and international markets efficiently.
7. Chongqing Kangle Pharmaceutical Co., Ltd.
Chongqing Kangle specializes in generic pharmaceuticals, including trihexyphenidyl, with a production volume of around 50 million units per year. The company is known for its competitive pricing strategies, which have garnered it a 4% market share domestically.
8. Sichuan Kangle Pharmaceutical Co., Ltd.
Sichuan Kangle has made significant strides in the generics market, producing 45 million tablets of trihexyphenidyl annually. The company holds about 3.5% of the domestic market and has begun expanding its export efforts into emerging markets.
9. Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Zhejiang Jianfeng produces around 40 million units of trihexyphenidyl each year. Although it holds a smaller market share of approximately 3%, the company is recognized for its quality assurance practices, which support its growth in international markets.
10. Yichang Humanwell Pharmaceutical Co., Ltd.
Yichang Humanwell has a diverse portfolio, including trihexyphenidyl, with an annual production capacity of around 30 million tablets. The company captures about 2.5% of the market share and is expanding its reach into European and American markets.
Insights and Trends
The trihexyphenidyl market in China is poised for continued growth, driven by increasing healthcare demands and advancements in production technologies. As of 2023, the overall market for trihexyphenidyl in China is projected to exceed USD 100 million, indicating a robust growth trajectory. The emphasis on generic medications is likely to enhance competition among manufacturers, leading to improved pricing and accessibility for healthcare providers. Moreover, the rise in partnerships with international pharmaceutical companies will further bolster export volumes, contributing to the global supply of trihexyphenidyl. The ongoing research into Parkinson’s disease treatments is expected to create new opportunities for manufacturers in the coming years.
Related Analysis: View Previous Industry Report
